Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESTRO 2025 | BRCA mutation management and breast cancer treatment options

Icro Meattini • 30 May 2025
ESTRO 2025
Breast Cancer

Icro Meattini, MD, University of Florence, Florence, Italy, comments on the management of breast cancer in BRCA mutation carriers, highlighting that germline BRCA mutations can be effectively managed with various treatments, including breast cancer, surgery, radiotherapy, or mastectomy, without significantly increasing the risk of death from breast cancer. Dr Meattini notes that BRCA1 carrier patients may require more aggressive surgical approaches, but overall, the risk of death from breast cancer is comparable to mastectomy alone. This interview took place at the ESTRO 2025 congress in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Icro Meattini

Early breast cancer: multimodal de-escalation strategies to reduce treatment burden safely
5:20
Early breast cancer: multimodal de-escalation strategies to reduce treatment burden safely
Icro Meattini • 10 Jul 2025
BRCA carrier status and radiation therapy in young patients with breast cancer
2:34
BRCA carrier status and radiation therapy in young patients with breast cancer
Icro Meattini • 30 May 2025
Moderate hypofractionation in high-risk breast cancer
3:07
Moderate hypofractionation in high-risk breast cancer
Icro Meattini • 30 May 2025
BRCA1 and BRCA2 carrier status: implications for breast cancer treatment
1:28
BRCA1 and BRCA2 carrier status: implications for breast cancer treatment
Icro Meattini • 30 May 2025

Related Videos

HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
QoL following hypofractionated adjuvant breast RNRT: insights from the HYPORT study
1:15
QoL following hypofractionated adjuvant breast RNRT: insights from the HYPORT study
Sanjoy Chatterjee • 17 May 2026
Adherence to weight loss intervention in breast cancer patients
1:09
Adherence to weight loss intervention in breast cancer patients
Jennifer Ligibel • 31 May 2026
The content of VJOncology is intended for healthcare professionals